Cytogenetics of Primary Skin Tumors

Chapter
Part of the Current Clinical Pathology book series (CCPATH)

Abstract

Skin tumors can arise as a result of cumulative genetic abnormalities, including chromosomal ­aberrations that can be described as either morphological (structural rearrangements) or molecular (copy number variations). Cytogenetic techniques have been used to examine both large and small chromosomal aberrations, and include karyotyping, comparative genomic hybridization, and fluorescence in situ hybridization. This chapter describes the recurrent aberrations associated with skin tumors, such as benign melanocytic nevi, melanoma, basal cell carcinoma, squamous cell carcinoma, actinic (solar) keratosis, Bowen’s disease, keratoacanthoma, Merkel cell carcinoma, dermatofibrosarcoma protuberans, and cutaneous lymphomas, as detected by cytogenetic methodologies. A significant number of genomic aberrations are shared across different subtypes of skin tumors, including structural and numerical alterations of chromosome 1, −3p, +3q, +6, +7, +8q, −9p, +9q, −10, −17p, +17q and +20. Aberrations specific to certain skin cancers have also been detected, and include: loss of 18q in squamous cell carcinoma, but not its precursor, actinic keratosis; loss of 9q22 in sporadic basal cell carcinoma; and translocation involving 17q22 and 22q13 in dermatofibrosarcoma protuberans. These regions contain a number of potential candidate genes that are involved in aspects of cell signaling, proliferation, differentiation, and apoptosis. Cytogenetic methodologies continue to evolve with the advent of array-based comparative genomic hybridization, copy number variation microarrays, and next-generation sequencing. It is envisioned that cytogenetic analysis will continue to be employed for identification and further exploration of novel chromosomal regions and associated genes that drive skin tumorigenesis.

References

  1. 1.
    Ford CE. Human cytogenetics: its present place and future possibilities. Am J Hum Genet. 1960;12:104–17.PubMedGoogle Scholar
  2. 2.
    Glassman AB. Cytogenetics, in situ hybridization and molecular approaches in the diagnosis of cancer. Ann Clin Lab Sci. 1998;28:324–30.PubMedGoogle Scholar
  3. 3.
    Haferlach C, Bacher U, Tiu R, et al. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing. Cancer Genet Cytogenet. 2008;187:101–11.PubMedGoogle Scholar
  4. 4.
    Folpe AL, Goldblum JR, Rubin BP, et al. Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases. Am J Surg Pathol. 2005;29:1025–33.PubMedGoogle Scholar
  5. 5.
    Nowell P, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science. 1960;132:1497.Google Scholar
  6. 6.
    Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290–3.PubMedGoogle Scholar
  7. 7.
    Mertens F, Heim S, Mandahl N, et al. Cytogenetic analysis of 33 basal cell carcinomas. Cancer Res. 1991;51:954–7.PubMedGoogle Scholar
  8. 8.
    Lotem M, Yehuda-Gafni O, Butnaryu E, et al. Cytogenetic analysis of melanoma cell lines: subclone selection in long-term melanoma cell cultures. Cancer Genet Cytogenet. 2003;142:87–91.PubMedGoogle Scholar
  9. 9.
    Kallioniemi OP, Kallioniemi A, Piper J, et al. Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosom Cancer. 1994;10:231–43.PubMedGoogle Scholar
  10. 10.
    Kallioniemi A, Visakorpi T, Karhu R, et al. Gene copy number analysis by fluorescence in situ hybridization and comparative genomic hybridization. Methods. 1996;9:113–21.PubMedGoogle Scholar
  11. 11.
    Thompson CT, Gray JW. Cytogenetic profiling using fluorescence in situ hybridization (FISH) and comparative genomic hybridization (CGH). J Cell Biochem Suppl. 1993;17G:139–43.PubMedGoogle Scholar
  12. 12.
    Varella-Garcia M. Molecular cytogenetics in solid tumors: laboratorial tool for diagnosis, prognosis, and therapy. Oncologist. 2003;8:45–58.PubMedGoogle Scholar
  13. 13.
    Happle R. Loss of heterozygosity in human skin. J Am Acad Dermatol. 1999;41:143–64.PubMedGoogle Scholar
  14. 14.
    Pinkel D, Segraves R, Sudar D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet. 1998;20:207–11.PubMedGoogle Scholar
  15. 15.
    Redon R, Ishikawa S, Fitch KR, et al. Global variation in copy number in the human genome. Nature. 2006;444:444–54.PubMedGoogle Scholar
  16. 16.
    Chen W, Kalscheuer V, Tzschach A, et al. Mapping translocation breakpoints by next-generation sequencing. Genome Res. 2008;18:1143–9.PubMedGoogle Scholar
  17. 17.
    Knutsen T, Gobu V, Knaus R, et al. The interactive online SKY/M-FISH & CGH database and the Entrez cancer chromosomes search database: linkage of chromosomal aberrations with the genome sequence. Genes Chromosom Cancer. 2005;44:52–64.PubMedGoogle Scholar
  18. 18.
    Mitelman F, Johansson B, Mertens F, editors. Mitelman database of chromosome aberrations in cancer. 2009. http://cgap.nci.nih.gov/Chromosomes/Mitelman. Accessed 25 Nov 2009.
  19. 19.
    Dorkeld F, Bernheim A, Dessen P, Huret JL. A database on cytogenetics in haematology and oncology. Nucleic Acids Res. 1999;27:353–354. http://atlasgeneticsoncology.org/. Accessed 27 Nov 2009.Google Scholar
  20. 20.
    Weinstock MA. Epidemiology of nonmelanoma skin cancer: clinical issues, definitions, and classification. J Invest Dermatol. 1994;102:4S–5S.PubMedGoogle Scholar
  21. 21.
    Burg G, Kempf W. Cutaneous B-cell lymphoma. eMedicine 2008. http://emedicine.medscape.com/article/1099540-overview. Accessed 12 Apr 2009.
  22. 22.
    American Cancer Society. Cancer facts and figures. Atlanta: American Cancer Society. http://www.cancer.org/downloads/STT/500809web.pdf (2009). Accessed 27 Nov 2009.
  23. 23.
    Hoglund M, Gisselsson D, Hansen GB, et al. Dissecting karyotypic patterns in malignant melanomas: temporal clustering of losses and gains in melanoma karyotypic evolution. Int J Cancer. 2004;108:57–65.PubMedGoogle Scholar
  24. 24.
    Bastian BC, Olshen AB, LeBoit PE, et al. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol. 2003;163:1765–70.PubMedGoogle Scholar
  25. 25.
    Richmond A, Fine R, Murray D, et al. Growth factor and cytogenetic abnormalities in cultured nevi and malignant melanomas. J Invest Dermatol. 1986;86:295–302.PubMedGoogle Scholar
  26. 26.
    Marras S, Faa G, Dettori T, et al. Chromosomal changes in dysplastic nevi. Cancer Genet Cytogenet. 1999;113:177–9.PubMedGoogle Scholar
  27. 27.
    Cowan JM, Francke U. Cytogenetic analysis in melanoma and nevi. Cancer Treat Res. 1991;54:3–16.PubMedGoogle Scholar
  28. 28.
    Balazs M, Adam Z, Treszl A, et al. Chromosomal imbalances in primary and metastatic melanomas revealed by comparative genomic hybridization. Cytometry. 2001;46:222–32.PubMedGoogle Scholar
  29. 29.
    Barks JH, Thompson FH, Taetle R, et al. Increased chromosome 20 copy number detected by fluorescence in situ hybridization (FISH) in malignant melanoma. Genes Chromosom Cancer. 1997;19:278–85.PubMedGoogle Scholar
  30. 30.
    Treszl A, Adany R, Rakosy Z, et al. Extra copies of c-myc are more pronounced in nodular melanomas than in superficial spreading melanomas as revealed by fluorescence in situ hybridisation. Cytom B Clin Cytom. 2004;60:37–46.Google Scholar
  31. 31.
    Matsuta M, Imamura Y, Matsuta M, et al. Detection of numerical chromosomal aberrations in malignant melanomas using fluorescence in situ hybridization. J Cutan Pathol. 1997;24:201–5.PubMedGoogle Scholar
  32. 32.
    Rakosy Z, Vizkeleti L, Ecsedi S, et al. EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis. Int J Cancer. 2007;121:1729–37.PubMedGoogle Scholar
  33. 33.
    Hussein MR, Roggero E, Tuthill RJ, et al. Identification of novel deletion Loci at 1p36 and 9p22-21 in melanocytic dysplastic nevi and cutaneous malignant melanomas. Arch Dermatol. 2003;139:816–7.PubMedGoogle Scholar
  34. 34.
    Uribe P, Wistuba II, Gonzalez S. Allelotyping, microsatellite instability, and BRAF mutation analyses in common and atypical melanocytic nevi and primary cutaneous melanomas. Am J Dermatopathol. 2009;31:354–63.PubMedGoogle Scholar
  35. 35.
    Hussein MR, Sun M, Roggero E, et al. Loss of heterozygosity, microsatellite instability, and mismatch repair protein alterations in the radial growth phase of cutaneous malignant melanomas. Mol Carcinog. 2002;34:35–44.PubMedGoogle Scholar
  36. 36.
    Udart M, Utikal J, Krahn GM, et al. Chromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases. Neoplasia. 2001;3:245–54.PubMedGoogle Scholar
  37. 37.
    Utikal J, Udart M, Leiter U, et al. Additional Cyclin D(1) gene copies associated with chromosome 11 aberrations in cutaneous malignant melanoma. Int J Oncol. 2005;26:597–605.PubMedGoogle Scholar
  38. 38.
    Krzywinski M, Schein J, Birol I, et al. Circos: an information aesthetic for comparative genomics. Genome Res. 2009;19:1639–45.PubMedGoogle Scholar
  39. 39.
    American Cancer Society. Overview: skin cancer – basal and squamous cell. How many people get basal and squamous cell skin cancers? 2008. http://www.cancer.org/docroot/CRI/content/CRI_2_2_1X_How_many_people_get_nonmelanoma_skin_cancer_51.asp?sitearea=. Accessed 27 Nov 2009.
  40. 40.
    Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol. 1994;30:774–8.PubMedGoogle Scholar
  41. 41.
    Wong CS, Strange RC, Lear JT. Basal cell carcinoma. BMJ. 2003;327:794–8.PubMedGoogle Scholar
  42. 42.
    Bernstein SC, Lim KK, Brodland DG, et al. The many faces of squamous cell carcinoma. Dermatol Surg. 1996;22:243–54.PubMedGoogle Scholar
  43. 43.
    Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol. 2002;146 Suppl 61:1–6.PubMedGoogle Scholar
  44. 44.
    Skidmore Jr RA, Flowers FP. Nonmelanoma skin cancer. Med Clin North Am. 1998;82:1309–23. vi.PubMedGoogle Scholar
  45. 45.
    Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000;42:4–7.PubMedGoogle Scholar
  46. 46.
    Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet. 1988;1:795–7.PubMedGoogle Scholar
  47. 47.
    Evans C, Cockerell CJ. Actinic keratosis: time to call a spade a spade. S Med J. 2000;93:734–6.Google Scholar
  48. 48.
    Frost C, Williams G, Green A. High incidence and regression rates of solar keratoses in a queensland community. J Invest Dermatol. 2000;115:273–7.PubMedGoogle Scholar
  49. 49.
    Ramrakha-Jones VS, Herd RM. Treating Bowen’s disease: a cost-minimization study. Br J Dermatol. 2003;148:1167–72.PubMedGoogle Scholar
  50. 50.
    Cohen PR. Bowen’s disease: squamous cell carcinoma in situ. Am Fam Physician. 1991;44:1325–9.PubMedGoogle Scholar
  51. 51.
    Reizner G, Chuang T, Elpern D, et al. Bowen’s disease (squamous cell carcinoma in situ) in Kauai, Hawaii. A population-based incidence report. J Am Acad Dermatol. 1994;31:596–600.PubMedGoogle Scholar
  52. 52.
    Reizner GT, Chuang TY, Elpern DJ, et al. Keratoacanthoma in Japanese Hawaiians in Kauai, Hawaii. Int J Dermatol. 1995;34:851–3.PubMedGoogle Scholar
  53. 53.
    Jin Y, Mertens F, Persson B, et al. Nonrandom numerical chromosome abnormalities in basal cell carcinomas. Cancer Genet Cytogenet. 1998;103:35–42.PubMedGoogle Scholar
  54. 54.
    Jin Y, Martins C, Salemark L, et al. Nonrandom karyotypic features in basal cell carcinomas of the skin. Cancer Genet Cytogenet. 2001;131:109–19.PubMedGoogle Scholar
  55. 55.
    Jin Y, Merterns F, Persson B, et al. The reciprocal translocation t(9;16)(q22;p13) is a primary chromosome abnormality in basal cell carcinomas. Cancer Res. 1997;57:404–6.PubMedGoogle Scholar
  56. 56.
    Kawasaki-Oyama RS, Andre FS, Caldeira LF, et al. Cytogenetic findings in two basal cell carcinomas. Cancer Genet Cytogenet. 1994;73:152–6.PubMedGoogle Scholar
  57. 57.
    Casalone R, Mazzola D, Righi R, et al. Cytogenetic and interphase FISH analyses of 73 basal cell and three squamous cell carcinomas: different findings in direct preparations and short-term cell cultures. Cancer Genet Cytogenet. 2000;118:136–43.PubMedGoogle Scholar
  58. 58.
    Ashton KJ, Weinstein SR, Maguire DJ, et al. Molecular cytogenetic analysis of basal cell carcinoma DNA using comparative genomic hybridization. J Invest Dermatol. 2001;117:683–6.PubMedGoogle Scholar
  59. 59.
    Quinn AG, Sikkink S, Rees JL. Basal cell carcinomas and squamous cell carcinomas of human skin show distinct patterns of chromosome loss. Cancer Res. 1994;54:4756–9.PubMedGoogle Scholar
  60. 60.
    Shen T, Park WS, Boni R, et al. Detection of loss of heterozygosity on chromosome 9q22.3 in microdissected sporadic basal cell carcinoma. Hum Pathol. 1999;30:284–7.PubMedGoogle Scholar
  61. 61.
    Shanley SM, Dawkins H, Wainwright BJ, et al. Fine deletion mapping on the long arm of chromosome 9 in sporadic and familial basal cell carcinomas. Hum Mol Genet. 1995;4:129–33.PubMedGoogle Scholar
  62. 62.
    Saridaki Z, Koumantaki E, Liloglou T, et al. High frequency of loss of heterozygosity on chromosome region 9p21-p22 but lack of p16INK4a/p19ARF mutations in Greek patients with basal cell carcinoma of the skin. J Invest Dermatol. 2000;115:719–25.PubMedGoogle Scholar
  63. 63.
    Ansarin H, Daliri M, Soltani-Arabshahi R. Expression of p53 in aggressive and non-aggressive histologic variants of basal cell carcinoma. Eur J Dermatol. 2006;16:543–7.PubMedGoogle Scholar
  64. 64.
    Bolshakov S, Walker CM, Strom SS, et al. p53 mutations in human aggressive and nonaggressive basal and squamous cell carcinomas. Clin Cancer Res. 2003;9:228–34.PubMedGoogle Scholar
  65. 65.
    Yu M, Zloty D, Cowan B, et al. Superficial, nodular, and morpheiform basal-cell carcinomas exhibit distinct gene expression profiles. J Invest Dermatol. 2008;128:1797–805.PubMedGoogle Scholar
  66. 66.
    Howell BG, Solish N, Lu C, et al. Microarray profiles of human basal cell carcinoma: insights into tumor growth and behavior. J Dermatol Sci. 2005;39:39–51.PubMedGoogle Scholar
  67. 67.
    Nangia R, Sait SN, Block AW, et al. Trisomy 6 in basal cell carcinomas correlates with metastatic potential: a dual color fluorescence in situ hybridization study on paraffin sections. Cancer. 2001;91:1927–32.PubMedGoogle Scholar
  68. 68.
    Fernandes H, Fernandes N, Bhattacharya S, et al. Molecular signatures linked with aggressive behavior in basal cell carcinoma: a report of 6 cases. Am J Dermatopathol. 2010;32(6):550–6.PubMedGoogle Scholar
  69. 69.
    Jin Y, Martins C, Jin C, et al. Nonrandom karyotypic features in squamous cell carcinomas of the skin. Genes Chromosom Cancer. 1999;26:295–303.PubMedGoogle Scholar
  70. 70.
    Ashton KJ, Weinstein SR, Maguire DJ, et al. Chromosomal aberrations in squamous cell carcinoma and solar keratoses revealed by comparative genomic hybridization. Arch Dermatol. 2003;139:876–82.PubMedGoogle Scholar
  71. 71.
    Popp S, Waltering S, Herbst C, et al. UV-B-type mutations and chromosomal imbalances indicate common pathways for the development of Merkel and skin squamous cell carcinomas. Int J Cancer. 2002;99:352–60.PubMedGoogle Scholar
  72. 72.
    Jin Y, Jin C, Salemark L, et al. Clonal chromosome abnormalities in premalignant lesions of the skin. Cancer Genet Cytogenet. 2002;136:48–52.PubMedGoogle Scholar
  73. 73.
    Rehman I, Takata M, Wu YY, et al. Genetic change in actinic keratoses. Oncogene. 1996;12:2483–90.PubMedGoogle Scholar
  74. 74.
    Lee HJ, Kim JS, Ha SJ, et al. p53 gene mutations in Bowen’s disease in Koreans: clustering in exon 5 and multiple mutations. Cancer Lett. 2000;158:27–33.PubMedGoogle Scholar
  75. 75.
    Mortier L, Marchetti P, Delaporte E, et al. Progression of actinic keratosis to squamous cell carcinoma of the skin correlates with deletion of the 9p21 region encoding the p16(INK4a) tumor suppressor. Cancer Lett. 2002;176:205–14.PubMedGoogle Scholar
  76. 76.
    Shimizu T, Izumi H, Oga A, et al. Epidermal growth factor receptor overexpression and genetic aberrations in metastatic squamous-cell carcinoma of the skin. Dermatology. 2001;202:203–6.PubMedGoogle Scholar
  77. 77.
    Kim DK, Kim JY, Kim HT, et al. A specific chromosome aberration in a keratoacanthoma. Cancer Genet Cytogenet. 2003;142:70–2.PubMedGoogle Scholar
  78. 78.
    Mertens F, Heim S, Mandahl N, et al. Clonal chromosome aberrations in a keratoacanthoma and a basal cell papilloma. Cancer Genet Cytogenet. 1989;39:227–32.PubMedGoogle Scholar
  79. 79.
    Clausen OP, Beigi M, Bolund L, et al. Keratoacanthomas frequently show chromosomal aberrations as assessed by comparative genomic hybridization. J Invest Dermatol. 2002;119:1367–72.PubMedGoogle Scholar
  80. 80.
    Waring AJ, Takata M, Rehman I, et al. Loss of heterozygosity analysis of keratoacanthoma reveals multiple differences from cutaneous squamous cell carcinoma. Br J Cancer. 1996;73:649–53.PubMedGoogle Scholar
  81. 81.
    Clausen OP, Aass HC, Beigi M, et al. Are keratoacanthomas variants of squamous cell carcinomas? A comparison of chromosomal aberrations by comparative genomic hybridization. J Invest Dermatol. 2006;126:2308–15.PubMedGoogle Scholar
  82. 82.
    Merkel cell carcinoma, information for patients and their physicians. What is Merkel cell carcinoma. 2009. http://www.merkelcell.org/aboutDisease/index.php. Accessed 30 Nov 2009.
  83. 83.
    Van Gele M, Speleman F, Vandesompele J, et al. Characteristic pattern of chromosomal gains and losses in Merkel cell carcinoma detected by comparative genomic hybridization. Cancer Res. 1998;58:1503–8.PubMedGoogle Scholar
  84. 84.
    Leonard JH, Leonard P, Kearsley JH. Chromosomes 1, 11, and 13 are frequently involved in karyotypic abnormalities in metastatic Merkel cell carcinoma. Cancer Genet Cytogenet. 1993;67:65–70.PubMedGoogle Scholar
  85. 85.
    Larramendy ML, Koljonen V, Bohling T, et al. Recurrent DNA copy number changes revealed by comparative genomic hybridization in primary Merkel cell carcinomas. Mod Pathol. 2004;17:561–7.PubMedGoogle Scholar
  86. 86.
    Vasuri F, Magrini E, Foschini MP, et al. Trisomy of chromosome 6 in Merkel cell carcinoma within lymph nodes. Virchows Arch. 2008;452:559–63.PubMedGoogle Scholar
  87. 87.
    Van Gele M, Leonard JH, Van Roy N, et al. Frequent allelic loss at 10q23 but low incidence of PTEN mutations in Merkel cell carcinoma. Int J Cancer. 2001;92:409–13.PubMedGoogle Scholar
  88. 88.
    Vortmeyer AO, Merino MJ, Boni R, et al. Genetic changes associated with primary Merkel cell carcinoma. Am J Clin Pathol. 1998;109:565–70.PubMedGoogle Scholar
  89. 89.
    Chen CJ, Siegel DM. Dermatofibrosarcoma protuberans. eMedicine 2009. http://emedicine.medscape.com/article/1100203-overview. Accessed 30 Nov 2009.
  90. 90.
    Kaur S, Vauhkonen H, Bohling T, et al. Gene copy number changes in dermatofibrosarcoma protuberans - a fine-resolution study using array comparative genomic hybridization. Cytogenet Genome Res. 2006;115:283–8.PubMedGoogle Scholar
  91. 91.
    Pedeutour F, Simon MP, Minoletti F, et al. Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: a new tumor-associated chromosome rearrangement. Cytogenet Cell Genet. 1996;72:171–4.PubMedGoogle Scholar
  92. 92.
    Pedeutour F, Coindre JM, Sozzi G, et al. Supernumerary ring chromosomes containing chromosome 17 sequences. A specific feature of dermatofibrosarcoma protuberans? Cancer Genet Cytogenet. 1994;76:1–9.PubMedGoogle Scholar
  93. 93.
    Kiuru-Kuhlefelt S, El-Rifai W, Fanburg-Smith J, et al. Concomitant DNA copy number amplification at 17q and 22q in dermatofibrosarcoma protuberans. Cytogenet Cell Genet. 2001;92:192–5.PubMedGoogle Scholar
  94. 94.
    Nishio J, Iwasaki H, Ohjimi Y, et al. Overrepresentation of 17q22-qter and 22q13 in dermatofibrosarcoma protuberans but not in dermatofibroma: a comparative genomic hybridization study. Cancer Genet Cytogenet. 2002;132:102–8.PubMedGoogle Scholar
  95. 95.
    The Leukemia and Lymphoma Society. Cutaneous T-cell lymphoma, vol 5. 2006. http://www.leukemia-lymphoma.org/attachments/National/br_1163608564.pdf. Accessed 12 Apr 2009.
  96. 96.
    Scarisbrick JJ, Woolford AJ, Russell-Jones R, et al. Allelotyping in mycosis fungoides and Sezary syndrome: common regions of allelic loss identified on 9p, 10q, and 17p. J Invest Dermatol. 2001;117:663–70.PubMedGoogle Scholar
  97. 97.
    Hoefnagel JJ, Dijkman R, Basso K, et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood. 2005;105:3671–8.PubMedGoogle Scholar
  98. 98.
    Mao X, Lillington D, Scarisbrick JJ, et al. Molecular cytogenetic analysis of cutaneous T-cell lymphomas: identification of common genetic alterations in Sezary syndrome and mycosis fungoides. Br J Dermatol. 2002;147:464–75.PubMedGoogle Scholar
  99. 99.
    Mao X, Lillington DM, Czepulkowski B, et al. Molecular cytogenetic characterization of Sezary syndrome. Genes Chromosom Cancer. 2003;36:250–60.PubMedGoogle Scholar
  100. 100.
    Barba G, Matteucci C, Girolomoni G, et al. Comparative genomic hybridization identifies 17q11.2 approximately q12 duplication as an early event in cutaneous T-cell lymphomas. Cancer Genet Cytogenet. 2008;184:48–51.PubMedGoogle Scholar
  101. 101.
    Gimenez S, Costa C, Espinet B, et al. Comparative genomic hybridization analysis of cutaneous large B-cell lymphomas. Exp Dermatol. 2005;14:883–90.PubMedGoogle Scholar
  102. 102.
    Streubel B, Scheucher B, Valencak J, et al. Molecular cytogenetic evidence of t(14;18)(IGH;BCL2) in a substantial proportion of primary cutaneous follicle center lymphomas. Am J Surg Pathol. 2006;30:529–36.PubMedGoogle Scholar
  103. 103.
    Hallermann C, Kaune KM, Gesk S, et al. Molecular cytogenetic analysis of chromosomal breakpoints in the IGH, MYC, BCL6, and MALT1 gene loci in primary cutaneous B-cell lymphomas. J Invest Dermatol. 2004;123:213–9.PubMedGoogle Scholar
  104. 104.
    Urban AE, Korbel JO, Selzer R, et al. High-resolution mapping of DNA copy alterations in human chromosome 22 using high-density tiling oligonucleotide arrays. Proc Natl Acad Sci USA. 2006;103:4534–9.PubMedGoogle Scholar
  105. 105.
    Stark M, Hayward N. Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res. 2007;67:2632–42.PubMedGoogle Scholar
  106. 106.
    Gijsbers AC, Lew JY, Bosch CA, et al. A new diagnostic workflow for patients with mental retardation and/or multiple congenital abnormalities: test arrays first. Eur J Hum Genet. 2009;17:1394–402.PubMedGoogle Scholar
  107. 107.
    Sabatino M, Zhao Y, Voiculescu S, et al. Conservation of genetic alterations in recurrent melanoma supports the melanoma stem cell hypothesis. Cancer Res. 2008;68:122–31.PubMedGoogle Scholar
  108. 108.
    Harvell JD, Kohler S, Zhu S, et al. High-resolution array-based comparative genomic hybridization for distinguishing paraffin-embedded Spitz nevi and melanomas. Diagn Mol Pathol. 2004;13:22–5.PubMedGoogle Scholar
  109. 109.
    Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24:4340–6.PubMedGoogle Scholar
  110. 110.
    Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135–47.PubMedGoogle Scholar
  111. 111.
    Ma C, Quesnelle KM, Sparano A, et al. Characterization CSMD1 in a large set of primary lung, head and neck, breast and skin cancer tissues. Cancer Biol Ther. 2009;8:907–16.PubMedGoogle Scholar
  112. 112.
    Hostetter G, Kim SY, Savage S, et al. Random DNA fragmentation allows detection of single-copy, single-exon alterations of copy number by oligonucleotide array CGH in clinical FFPE samples. Nucleic Acids Res. 2010;38:e9.PubMedGoogle Scholar
  113. 113.
    Purdie KJ, Lambert SR, Teh MT, et al. Allelic imbalances and microdeletions affecting the PTPRD gene in cutaneous squamous cell carcinomas detected using single nucleotide polymorphism microarray analysis. Genes Chromosom Cancer. 2007;46:661–9.PubMedGoogle Scholar
  114. 114.
    Teh MT, Blaydon D, Chaplin T, et al. Genomewide single nucleotide polymorphism microarray mapping in basal cell carcinomas unveils uniparental disomy as a key somatic event. Cancer Res. 2005;65:8597–603.PubMedGoogle Scholar
  115. 115.
    Paulson KG, Lemos BD, Feng B, et al. Array-CGH reveals recurrent genomic changes in Merkel cell carcinoma including amplification of L-Myc. J Invest Dermatol. 2009;129:1547–55.PubMedGoogle Scholar
  116. 116.
    Sastre-Garau X, Peter M, Avril MF, et al. Merkel cell carcinoma of the skin: pathological and molecular evidence for a causative role of MCV in oncogenesis. J Pathol. 2009;218:48–56.PubMedGoogle Scholar
  117. 117.
    Salgado R, Servitje O, Gallardo F, et al. Oligonucleotide Array-CGH Identifies Genomic Subgroups and Prognostic Markers for Tumor Stage Mycosis Fungoides. J Invest Dermatol. 2010;130:1126–35.PubMedGoogle Scholar
  118. 118.
    Pekarsky Y, Garrison PN, Palamarchuk A, et al. Fhit is a physiological target of the protein kinase Src. Proc Natl Acad Sci USA. 2004;101:3775–9.PubMedGoogle Scholar
  119. 119.
    Deweindt C, Albagli O, Bernardin F, et al. The LAZ3/BCL6 oncogene encodes a sequence-specific transcriptional inhibitor: a novel function for the BTB/POZ domain as an autonomous repressing domain. Cell Growth Differ. 1995;6:1495–503.PubMedGoogle Scholar
  120. 120.
    Nevins JR. Toward an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth Differ. 1998;9:585–93.PubMedGoogle Scholar
  121. 121.
    Leone G, Sears R, Huang E, et al. Myc requires distinct E2F activities to induce S phase and apoptosis. Mol Cell. 2001;8:105–13.PubMedGoogle Scholar
  122. 122.
    Santos GC, Zielenska M, Prasad M, et al. Chromosome 6p amplification and cancer progression. J Clin Pathol. 2007;60:1–7.PubMedGoogle Scholar
  123. 123.
    Meyerson M, Harlow E. Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol. 1994;14:2077–86.PubMedGoogle Scholar
  124. 124.
    Okamoto I, Pirker C, Bilban M, et al. Seven novel and stable translocations associated with oncogenic gene expression in malignant melanoma. Neoplasia. 2005;7:303–11.PubMedGoogle Scholar
  125. 125.
    Felsher DW, Bishop JM. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc Natl Acad Sci USA. 1999;96:3940–4.PubMedGoogle Scholar
  126. 126.
    Karlsson A, Deb-Basu D, Cherry A, et al. Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression. Proc Natl Acad Sci USA. 2003;100:9974–9.PubMedGoogle Scholar
  127. 127.
    Sharpless NE. INK4a/ARF: a multifunctional tumor suppressor locus. Mutat Res. 2005;576:22–38.PubMedGoogle Scholar
  128. 128.
    Li DM, Sun H. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci USA. 1998;95:15406–11.PubMedGoogle Scholar
  129. 129.
    Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943–7.PubMedGoogle Scholar
  130. 130.
    Hickman ES, Moroni MC, Helin K. The role of p53 and pRB in apoptosis and cancer. Curr Opin Genet Dev. 2002;12:60–6.PubMedGoogle Scholar
  131. 131.
    Bourdon JC. p53 and its isoforms in cancer. Br J Cancer. 2007;97:277–82.PubMedGoogle Scholar
  132. 132.
    Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol. 2007;8:275–83.PubMedGoogle Scholar
  133. 133.
    Platzer P, Upender MB, Wilson K, et al. Silence of chromosomal amplifications in colon cancer. Cancer Res. 2002;62:1134–8.PubMedGoogle Scholar
  134. 134.
    Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature. 1997;390:465–71.PubMedGoogle Scholar
  135. 135.
    Miyaki M, Kuroki T. Role of Smad4 (DPC4) inactivation in human cancer. Biochem Biophys Res Commun. 2003;306:799–804.PubMedGoogle Scholar
  136. 136.
    Tian F, DaCosta SB, Parks WT, et al. Reduction in Smad2/3 signaling enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Cancer Res. 2003;63:8284–92.PubMedGoogle Scholar
  137. 137.
    Bale AE, Yu KP. The hedgehog pathway and basal cell carcinomas. Hum Mol Genet. 2001;10:757–62.PubMedGoogle Scholar
  138. 138.
    Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature. 1999;401:86–90.PubMedGoogle Scholar
  139. 139.
    Shimizu A, O’Brien KP, Sjoblom T, et al. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res. 1999;59:3719–23.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Genomics Research Centre, GIHMR, School of Medical ScienceGriffith University-Gold CoastBundallAustralia

Personalised recommendations